Isthmus Partners LLC Takes Position in DexCom, Inc. $DXCM

Isthmus Partners LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 167,387 shares of the medical device company’s stock, valued at approximately $14,611,000. DexCom accounts for approximately 1.7% of Isthmus Partners LLC’s investment portfolio, making the stock its 17th largest position.

Several other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Andra AP fonden bought a new position in shares of DexCom during the 2nd quarter worth approximately $26,000. Zions Bancorporation National Association UT acquired a new stake in DexCom during the 1st quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the second quarter worth $45,000. Anderson Financial Strategies LLC bought a new position in DexCom during the first quarter worth $37,000. Finally, Atlantic Union Bankshares Corp acquired a new position in shares of DexCom in the second quarter valued at $70,000. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on DXCM shares. Oppenheimer downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Sanford C. Bernstein restated an “outperform” rating and set a $84.00 price objective on shares of DexCom in a report on Monday, November 3rd. Barclays set a $80.00 target price on DexCom and gave the stock an “equal weight” rating in a research note on Monday, November 3rd. Stifel Nicolaus began coverage on DexCom in a report on Tuesday, October 21st. They set a “buy” rating and a $85.00 price target for the company. Finally, Cowen reaffirmed a “buy” rating on shares of DexCom in a report on Friday, October 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $87.27.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $63.52 on Tuesday. The business has a fifty day moving average price of $64.19 and a two-hundred day moving average price of $75.60. The stock has a market capitalization of $24.77 billion, a PE ratio of 44.11, a P/E/G ratio of 1.43 and a beta of 1.40. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter last year, the business earned $0.45 earnings per share. DexCom’s revenue was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the transaction, the director owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. The trade was a 3.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kyle Malady sold 667 shares of the company’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the sale, the director owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 9,999 shares of company stock valued at $619,391 over the last three months. 0.32% of the stock is owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.